Sign inJoin waitlistJoin the waitlist

Ann Melvin

Pediatrics / Pediatric Infectious Diseases

Credentials: · ·

History

Pediatric Infectious Diseases
1999–2002
Pediatrics
1996–1999
Tulane University School of Medicine
1992–1996

Research

Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus
Journal of Virology · 2005 · 190 citations
Differentiation of the T helper phenotypes by analysis of the methylation state of the IFN-gamma gene
The Journal of Immunology · 1994 · 152 citations
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected…
The Lancet Infectious Diseases · 2011 · 111 citations

Lisa Frenkel
21 papers · 5 as a resident
Elizabeth McFarland
6 papers
Nicole Tobin
6 papers · 1 as a fellow
Anna Wald
4 papers
Jane Hitti
4 papers · 1 as a fellow
SB
Sandra Burchett
4 papers
David Lewis
3 papers
Elizabeth Livingston
3 papers
GS
George Siberry
3 papers
Grace McComsey
3 papers
HS
Hans Spiegel
3 papers
PL
Paul Lewis
3 papers

Grants

NextGen Long-Acting and Targeted Combination ART for Children with HIV
National Institute of Allergy and Infectious Diseases · R33
PI · $2.7M · University of Washington
2020–2026
NextGen Long-Acting and Targeted Combination ART for Children with HIV
National Institute of Allergy and Infectious Diseases · R61
PI · $2.1M · University of Washington
2020–2022
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $12.4K · University of Washington
2006–2007
Developmental Regulation of Interferon Gamma
National Institute of Child Health and Human Development · F32
Contact PI · $60.3K · Seattle Children's Hospital
1991

Clinical trials

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents
Study chair · Completed · Phase 1, Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2018–2022
Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age
Study chair · Withdrawn · Phase 1, Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2014
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Study chair · Terminated · Phase 1, Phase 2
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
2009–2014
Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children
Study chair · Completed · Phase 2, Phase 3
National Institute of Allergy and Infectious Diseases (NIAID)
2002–2010